Suffcient Treatment Of Peripheral Intervention by Cilostazol - STOP-IC

Independent Administrative Institute/Japan Labour Health and Welfare Organization, Kansai Rosai Hosp0 个研究点目标入组 200 人开始时间: 2009年6月18日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Exclusion criteria Patient criteria Patients who meet any of the following criteria should be excluded from the study: 1.Patients with or at risk of hemorrhagic complications or patients with bleeding* tendency *Bleeding such as hemophilia, capillary fragility, intracranial hemorrhage, gastrointestinal hemorrhage, urinary tract hemorrhage, hemoptysis, or vitreous hemorrhage may be aggravated. 2.Patients with congestive cardiac failure (NYHA III or IV or EF<30%) 3.Patients with a drug-eluting stent (DES) 4.Patients with creatinine of 2 mg/dL or patients with a history of serious adverse reaction such as leukopenia, hepatic dysfunction, or renal dysfunction, or hypersensitivity to any component of the study drug. 5.Pregnant or potentially pregnant women 6.Patients with acute lower limb ischemia 7.Patients who are not eligible for the study in the opinion of the attending physician. Lesion criteria Lesions that meet any of the following criteria should be excluded from the study: 1.Remnant inflow (aorta-iliac artery lesion) 2.Severe calcification (lesions not expected to be appropriately expanded) 3.No arterial runoff below the knee

发起方

Independent Administrative Institute/Japan Labour Health and Welfare Organization, Kansai Rosai Hosp